PE21896A1 - PROCEDIMIENTO PARA LA PREPARACION DE INSULINA HUMANA-LysB28ProB29 CRISTALINA - Google Patents

PROCEDIMIENTO PARA LA PREPARACION DE INSULINA HUMANA-LysB28ProB29 CRISTALINA

Info

Publication number
PE21896A1
PE21896A1 PE1995271264A PE27126495A PE21896A1 PE 21896 A1 PE21896 A1 PE 21896A1 PE 1995271264 A PE1995271264 A PE 1995271264A PE 27126495 A PE27126495 A PE 27126495A PE 21896 A1 PE21896 A1 PE 21896A1
Authority
PE
Peru
Prior art keywords
human insulin
procedure
crystalline
preparation
phenolic
Prior art date
Application number
PE1995271264A
Other languages
English (en)
Spanish (es)
Inventor
Nancy Delores Carter
Jeffrey Clayton Baker
Bruce Hill Frank
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22990041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE21896(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE21896A1 publication Critical patent/PE21896A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PE1995271264A 1994-06-16 1995-06-14 PROCEDIMIENTO PARA LA PREPARACION DE INSULINA HUMANA-LysB28ProB29 CRISTALINA PE21896A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,647 US5504188A (en) 1994-06-16 1994-06-16 Preparation of stable zinc insulin analog crystals

Publications (1)

Publication Number Publication Date
PE21896A1 true PE21896A1 (es) 1996-06-15

Family

ID=22990041

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995271264A PE21896A1 (es) 1994-06-16 1995-06-14 PROCEDIMIENTO PARA LA PREPARACION DE INSULINA HUMANA-LysB28ProB29 CRISTALINA

Country Status (29)

Country Link
US (1) US5504188A (en, 2012)
EP (1) EP0692489B1 (en, 2012)
JP (1) JP3595607B2 (en, 2012)
KR (1) KR100369951B1 (en, 2012)
CN (1) CN1184234C (en, 2012)
AT (1) ATE233278T1 (en, 2012)
AU (1) AU697794B2 (en, 2012)
BR (1) BR9502798A (en, 2012)
CA (1) CA2151563C (en, 2012)
CO (1) CO4410205A1 (en, 2012)
CZ (1) CZ286066B6 (en, 2012)
DE (1) DE69529708T2 (en, 2012)
DK (1) DK0692489T3 (en, 2012)
ES (1) ES2188637T3 (en, 2012)
FI (1) FI952930L (en, 2012)
HU (1) HUT73495A (en, 2012)
IL (1) IL114152A (en, 2012)
IN (1) IN178919B (en, 2012)
MY (1) MY130551A (en, 2012)
NO (1) NO952334L (en, 2012)
NZ (1) NZ272358A (en, 2012)
PE (1) PE21896A1 (en, 2012)
PL (1) PL180968B1 (en, 2012)
RO (1) RO113529B1 (en, 2012)
RU (1) RU2156257C2 (en, 2012)
SI (1) SI0692489T1 (en, 2012)
TW (1) TW379228B (en, 2012)
YU (1) YU39595A (en, 2012)
ZA (1) ZA954942B (en, 2012)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5869604A (en) * 1995-11-09 1999-02-09 Georgia Institute Of Technology Crystallization and purification of polypeptides
JP2001518915A (ja) * 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
WO1999024015A1 (en) * 1997-11-12 1999-05-20 Alza Corporation Buffered drug formulations for transdermal electrotransport delivery
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
AU758108B2 (en) * 1998-10-16 2003-03-13 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
DE69920767T2 (de) * 1998-10-16 2006-02-02 Novo Nordisk A/S Stabile konzentrierte Insulin Präparationen zur pulmonaren Verabreichung
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
DK1358209T3 (da) * 2001-02-09 2007-05-07 Genentech Inc Krystallisering af IGF-1
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
JP4563675B2 (ja) 2001-10-12 2010-10-13 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 置換ピペリジン類、およびヒスタミンｈ３受容体関連疾患の治療のためのその使用
WO2003105768A2 (en) * 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
ATE482747T1 (de) 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
AU2004290862B2 (en) 2003-11-20 2010-06-03 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
PL2626368T3 (pl) 2004-07-19 2017-06-30 Biocon Limited Koniugaty insulina-oligomer, ich formulacje i zastosowania
KR20070085227A (ko) * 2004-08-09 2007-08-27 앨리오스 바이오파마 인크. 합성 초글리코실화, 프로테아제 저항성 폴리펩티드 변이체,경구 제제 및 이를 이용한 방법
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
WO2007123581A1 (en) 2005-11-17 2007-11-01 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
EP1996224B1 (en) 2006-03-15 2012-11-07 Novo Nordisk A/S Mixtures of amylin and insulin
US8394842B2 (en) 2006-03-28 2013-03-12 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
ES2378574T3 (es) 2006-04-24 2012-04-16 Eli Lilly & Company Pirrolidinonas ciclohexilo substituidas como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
BRPI0711370A2 (pt) 2006-05-29 2011-11-01 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)pi ridazina e seus sais e solvatos e seu uso como antagonista receptor h3 de histamina
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2008145730A1 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
US9034818B2 (en) * 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
ES2664822T3 (es) * 2007-10-16 2018-04-23 Biocon Limited Una composición farmacéutica sólida administrable por vía oral y un proceso de la misma
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
EP2362730A4 (en) 2008-11-21 2012-08-29 High Point Pharmaceuticals Llc Adamantyl BENZAMIDE CONNECTIONS
CA2750262C (en) 2009-01-28 2016-08-09 Smartcells, Inc. Conjugate based systems for controlled drug delivery
US8940690B2 (en) 2009-01-28 2015-01-27 National Institutes Of Health (Nih) Synthetic conjugates and uses thereof
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
RU2508294C2 (ru) * 2009-08-11 2014-02-27 Биокон Лимитед Хроматографические способы и соединения, очищенные этими способами
BR112013019508A2 (pt) 2011-02-01 2016-08-30 Novo Nordisk As purificação de insulina
US10130684B2 (en) 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
CN103342746B (zh) * 2013-07-26 2014-07-30 珠海联邦制药股份有限公司 一种制备稳定的门冬胰岛素结晶的方法
US9822158B2 (en) 2013-12-04 2017-11-21 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
EP2990033A1 (fr) * 2014-08-26 2016-03-02 Carlina Technologies Procédé de préparation de nanoprécipites de peptide ou protéine de faible poids moléculaire
EP3185887B1 (en) 2014-08-26 2021-03-10 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
CN104193819B (zh) * 2014-09-03 2017-05-17 韩飞 胰岛素二聚体晶体的合成和保存方法
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
CN104892749B (zh) * 2015-06-16 2019-02-05 珠海联邦制药股份有限公司 一种德谷胰岛素结晶的制备方法及应用
CN105753966A (zh) * 2016-05-05 2016-07-13 通化东宝药业股份有限公司 一种重组人胰岛素结晶的制备方法
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
EP3740212A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
CR20220555A (es) 2020-03-31 2023-01-23 Protomer Tech Inc Conjugados para reactividad selectiva a dioles vecinales
KR20230110505A (ko) 2020-11-19 2023-07-24 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 인슐린 유사체
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品
IL317049A (en) 2022-05-18 2025-01-01 Protomer Tech Inc Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE515508A (en, 2012) *
BE533298A (en, 2012) *
BE533252A (en, 2012) *
US2143590A (en) * 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2920104A (en) 1958-07-01 1960-01-05 Vanderbilt Co R T Stabilized solutions of a dithiocarbamate
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
EP0425482B1 (en) * 1988-07-20 1993-08-18 Novo Nordisk A/S Human insulin analogs and preparations containing them
HUT56857A (en) * 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
EP1132404A3 (en) * 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas

Also Published As

Publication number Publication date
CZ154195A3 (en) 1996-02-14
TW379228B (en) 2000-01-11
FI952930A0 (fi) 1995-06-14
JPH08169899A (ja) 1996-07-02
CN1128271A (zh) 1996-08-07
KR100369951B1 (ko) 2003-03-28
RU95110107A (ru) 1997-05-10
ES2188637T3 (es) 2003-07-01
ATE233278T1 (de) 2003-03-15
HU9501715D0 (en) 1995-08-28
FI952930A7 (fi) 1995-12-17
IL114152A (en) 1999-12-31
EP0692489A1 (en) 1996-01-17
EP0692489B1 (en) 2003-02-26
RU2156257C2 (ru) 2000-09-20
BR9502798A (pt) 1996-06-04
AU2168195A (en) 1996-01-04
HUT73495A (en) 1996-08-28
CZ286066B6 (cs) 2000-01-12
JP3595607B2 (ja) 2004-12-02
AU697794B2 (en) 1998-10-15
CN1184234C (zh) 2005-01-12
IN178919B (en, 2012) 1997-07-19
CA2151563C (en) 2007-08-07
PL309099A1 (en) 1995-12-27
DE69529708D1 (de) 2003-04-03
YU39595A (sh) 1997-08-22
MY130551A (en) 2007-06-29
NO952334L (no) 1995-12-18
CA2151563A1 (en) 1995-12-17
CO4410205A1 (es) 1997-01-09
SI0692489T1 (en) 2003-06-30
DE69529708T2 (de) 2003-10-16
PL180968B1 (pl) 2001-05-31
IL114152A0 (en) 1995-10-31
RO113529B1 (ro) 1998-08-28
US5504188A (en) 1996-04-02
NO952334D0 (no) 1995-06-13
NZ272358A (en) 1996-12-20
DK0692489T3 (da) 2003-03-31
ZA954942B (en) 1996-12-17
KR960000922A (ko) 1996-01-25
FI952930L (fi) 1995-12-17

Similar Documents

Publication Publication Date Title
PE21896A1 (es) PROCEDIMIENTO PARA LA PREPARACION DE INSULINA HUMANA-LysB28ProB29 CRISTALINA
ATE293967T1 (de) Zusammensetzungen enthaltend stilbenoide mit einer hypoglykämischen wirkung
AR019876A1 (es) Uso de una solucion liquida desinfectante que contiene un compuesto antimicrobiano para la desinfeccion composicion desinfectante que lo contiene
ES8503015A1 (es) Una composicion de organopolisiloxano vulcanizable a la temperatura ambiente.
DE69000659D1 (de) Zusammensetzungen fuer in situ hergestellte kalziumphosphatmineralien.
AR057610A2 (es) Composiciones anestesicas de sevoflurano, metodo para su preparacion, metodos para inhibir su degradacion ante la presencia de un acido lewis y un proceso para preparar una composicion anestesica estable en un contenedor sellado
CO5580785A2 (es) Sal sodica cristalina del telmisartan y su uso como antagonista de angiotensina
PE20000477A1 (es) Procedimiento para la preparacion de (s,s)-bencil-2,8-diazabiciclo[4.3.0)nonano
ES8301978A1 (es) Un procedimiento para la preparacion de 2-guanidino-4-heteroaril-tiazoles.
ES2195332T3 (es) Metodo de cristalizacion.
Phillips et al. The preparation of alkylguanidines
Homeyer et al. Preparation of tert-Butylacetic Acid and its Derivatives
ES2002112A6 (es) Un metodo para preparar sales cristalinas de cefalosporinas semisinteticas, particularmente de 7-(alfa-(2-aminotiazol-4-il)-alfa-(z)-metoximinoacetamido)-3-((1-metil-1-pirrolidinio)-metil)-3-cefem-4-carboxilato
PT98604A (pt) Processo para a preparacao de uma solucao estavel de hipoclorito de sodio
ES2075399T3 (es) Hemihidrato.
ES8300332A1 (es) Un procedimiento para la preparacion de nuevos derivados de imidazoquinazolinas
Price et al. The Alkylation of Benzene with ds-Butyl Alcohol
ES2085923T3 (es) Procedimiento para la preparacion de poliamidas aromaticas con elevada estabilidad frente a la hidrolisis.
ES8307827A1 (es) "procedimiento para la preparacion de tiazolo(3,2-a)pirimidinas sustituidas".
IT1113029B (it) Processo per la separazione dei due isomeri ottici del moprololo e composizioni farmaceutiche dell'antipodo levogiro
Ekeley et al. Some Double Salts of Indium and Organic Bases
ES8302647A1 (es) Un procedimiento para la preparacion de guanidinas
ES2145475T3 (es) Procedimiento para nitrar compuestos de eter difenilico.
BR8707031A (pt) Composicao microbicida,desinfetante de sementes,sementes;processo para a preparacao de um sal de acido pirofosforoso,sais de acido pirofosforoso,compostos,processo para combater ou impedir uma infestacao
ES2107050T3 (es) Procedimiento para la preparacion de sulfonatos.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed